Received Jun 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | Y013407 | — |
No other AE; HBP calling to report AE. 17 year old patient inadvertently received a 3rd dose of the GARDASIL 9 vaccine. 1st dose: March 31st, 2021 2nd dose: October 25, 2022 3rd dose: May 19th, 2025 No further information provided. No other AE/No PQC.; 2nd dose: October 25, 2022; This spontaneous report was received from a/an Consumer or other non health professional and refers to a(n) 17-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 31-Mar-2021, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (lot #, expiration date, exact dose, route of administration and anatomical location were not provided) for prophylaxis. On 25-Oct-2022, the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9) (lot #, expiration date, exact dose, route of administration and anatomical location were not provided) for prophylaxis (inappropriate schedule of product administration). On 19-May-2025, the patient was vaccinated with the third dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), lot #Y013407, expiration date: 01-Feb-2027, 0.5 mL (route of administration and anatomical location were not provided) for prophylaxis (inappropriate schedule of product administration). No additional adverse event reported (no adverse event).